Investigational drug · Phase 3
Alflutinib Mesylate
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Apr 11, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
18
Any phase or sponsor naming "Alflutinib Mesylate"
First trial start
2019
May 30, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Alflutinib Mesylate", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Alflutinib Mesylate" as an intervention, largest first.
MediLink Therapeutics (Suzhou) Co., Ltd.Industry
NCT07169994 · 414 participants (planned) · Start Sep 2, 2025 · Primary completion Sep 1, 2026
Drug: YL202 for injection; Toripalimab injection; YL202 for injection; Furmonertinib Mesilate Tablets · For: Advanced Solid Tumors; Breast Cancer; Non Small Cell Lung Cancer
Sites: Hefei, China; Fuzhou, China; Guangzhou, China · 20 sites in all
Allist Pharmaceuticals, Inc.Industry
NCT06970639 · 380 participants (planned) · Start Sep 26, 2024 · Primary completion Mar 2029
Drug: Furmonertinib Mesilate Tablets; Carboplatin Injection and 3 more · For: NSCLC Patients With Brain Metastasis
Sites: Guangdong, China
- Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAG)Pivotal-lookingActive, not recruiting
Allist Pharmaceuticals, Inc.Industry
NCT03787992 · 358 participants · Start May 30, 2019 · Primary completion Sep 15, 2021
Drug: Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo; Placebo Gefitinib 250 mg and 2 more · For: Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Sites: Beijing, China
- A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung CancerPivotal-lookingRecruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT07229729 · 300 participants (planned) · Start Nov 24, 2025 · Primary completion Oct 2026
Drug: SHR-A2102; Adebrelimab and 5 more · For: Non-small Cell Lung Cancer
Sites: Guangzhou, China
Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
NCT06868732 · 288 participants (planned) · Start Apr 2, 2025 · Primary completion Jun 30, 2028
Drug: JSKN016; Carboplatin and 5 more · For: Advanced Non-small Cell Lung Cancer
Sites: Guangzhou, China
- Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNAPivotal-lookingRecruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT05334277 · 280 participants (planned) · Start May 6, 2022 · Primary completion Feb 28, 2025
Drug: Furmonertinib; Furmonertinib and 2 more · For: Non-small Cell Lung Cancer
Sites: Changchun, China; Chengdu, China; Dongguan, China · 26 sites in all
Allist Pharmaceuticals, Inc.Industry
NCT04858958 · 90 participants · Start Aug 10, 2020 · Primary completion Dec 5, 2024
Drug: Furmonertinib 160mg; Furmonertinib 240mg · For: NSCLC
Sites: Shanghai, China
RemeGen Co., Ltd.Industry
NCT06962865 · 80 participants (planned) · Start Jun 30, 2025 · Primary completion May 31, 2026
Drug: RC108; Furmonertinib Mesilate Tablets Monotherapy · For: Non-Small Cell Lung Cancer
Sites: Beijing, China; Binzhou, China; Changchun, China · 34 sites in all
- Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLCRecruiting
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT05987826 · 40 participants (planned) · Start Sep 19, 2023 · Primary completion Aug 2028
Drug: Furmonertinib · For: Non-Small Cell Lung Cancer
Sites: Shanghai, China
- Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)Status unknown
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT04965831 · 40 participants (planned) · Start Aug 1, 2021 · Primary completion Mar 1, 2023
Drug: Furmonertinib · For: Lung Adenocarcinoma
Newest research
PubMed records naming it or its code names, newest first.
- Patient-derived organoid models of malignant phyllodes tumours for drug sensitivity testing and identification of targeted therapeutic strategies.
Chen J, Liu L, Yang Y, et al. · J Drug Target 2025
- A Randomized, Open, Single-Centre, Crossed Study of the Effect of Food on the Pharmacokinetics of One Oral Dose of Alflutinib Mesylate Tablets (AST2818) in Healthy Male Subjects.
Zhu S, Deng J, Tang Q, et al. · Iran J Pharm Res 2020
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.